REGN Share Price

Open 359.88 Change Price %
High 361.08 1 Day 0.05 0.01
Low 355.00 1 Week -10.17 -2.74
Close 361.01 1 Month 12.08 3.46
Volume 717168 1 Year -32.98 -8.37
52 Week High 452.96
52 Week Low 325.35
REGN Important Levels
Resistance 2 366.65
Resistance 1 364.32
Pivot 359.03
Support 1 357.70
Support 2 355.37
NASDAQ USA Most Active Stocks
DRYS 2.24 -4.68%
FNFG 10.18 -0.20%
DELL 13.86 0.22%
RFMD 16.59 -2.07%
RIMM 13.03 0.39%
BBEP 0.12 0.00%
GTAT 0.44 0.00%
SUSQ 14.20 -0.77%
ACAS 17.99 0.39%
ASTI 0.00 0.00%
More..
NASDAQ USA Top Gainers Stocks
MYRX 0.10 100.00%
LOCM 0.09 50.00%
CEMP 4.05 28.57%
WRES 0.09 28.57%
BSDM 0.62 26.53%
SNTA 0.34 25.93%
OTT 2.39 25.13%
SKBI 0.10 25.00%
IPCI 2.55 18.60%
QKLS 0.15 15.38%
More..
NASDAQ USA Top Losers Stocks
TXCC 0.01 -95.00%
HCIIP 10.10 -67.52%
GMETP 0.70 -59.54%
CRMB 0.27 -57.81%
KIOR 0.03 -57.14%
EDMC 0.01 -50.00%
QTWW 0.08 -50.00%
SPIR 0.01 -50.00%
OSH 0.26 -49.02%
OSH 0.26 -49.02%
More..

Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN)

REGN Technical Analysis 3
As on 24th Feb 2017 REGN Share Price closed @ 361.01 and we RECOMMEND Sell for LONG-TERM with Stoploss of 384.23 & Sell for SHORT-TERM with Stoploss of 367.09 we also expect STOCK to react on Following IMPORTANT LEVELS.
REGN Target for February
1st Target up-side 386.07
2nd Target up-side 404.83
3rd Target up-side 423.6
1st Target down-side 332.51
2nd Target down-side 313.75
3rd Target down-side 294.98
REGN Other Details
Segment EQ
Market Capital 13942355968.00
Sector Healthcare
Industry Biotechnology
Offical website http://www.regeneron.com
REGN Address
REGN
777 Old Saw Mill River Road
Tarrytown, NY 10591
United States
Phone: 914-347-7000
REGN Latest News
Interactive Technical Analysis Chart Regeneron Pharmaceuticals, Inc. ( REGN NASDAQ USA )
Java support must be enabled in order to display FnCharts.
You can download Java from http://www.java.com
Your Comments and Response on Regeneron Pharmaceuticals, Inc.
REGN Business Profile
Regeneron Pharmaceuticals, Inc. (Regeneron) is an integrated biopharmaceutical company, which discovers, invents, develops, manufactures, and commercializes medicines for the treatment of serious medical conditions. As of December 31, 2011, the Company had two marketed products: EYLEA (aflibercept) Injection and ARCALYST (rilonacept) Injection for Subcutaneous Use. As of December 31, 2011, the Company had 13 product candidates in clinical development. Its Trap-based, late-stage programs are EYLEA, which is being developed for the treatment of additional serious eye diseases; ZALTRAP (aflibercept), known in the scientific literature as vascular endothelial growth factor (VEGF) trap, which is being developed in oncology in collaboration with Sanofi; and ARCALYST, which is being developed for the prevention of gout flares in patients initiating uric acid-lowering treatment.